Supplementary Table 7.

Main society/association guidelines/consensus statement’s recommendation on the association between testosterone-replacing therapy and cardiovascular/thromboembolic risk

Society/association	CV/thromboembolic risk	Recommendation against TRT	Prior to TRT
AUA	At this time, it cannot be stated definitively whether testosterone therapy increases or decreases the risk of CV events	Recent (3–6 months) CV event Hematocrit >54%	Hematocrit evaluation Inform patients that there is no substantive evidence of the increased risk of CV events with TRT
AACE	No specific recommendations on this issue are possible until further research clarifies the potential risks and benefits of therapy	Hematocrit >50%	Hematocrit evaluation
BSSM	Undefined	Hematocrit >54%	Hematocrit evaluation
EAA	When hypogonadism is properly diagnosed and managed, there is currently no consistent evidence of an increased risk of CV disease during TRT	Recent major acute CV event Severe heart failure Polycythemia Hematocrit >48%–50%	Hematocrit evaluation Obtain a detailed family and personal history of VTE and associated risk factors
ES	Undefined	Hematocrit<48%	Hematocrit evaluation
EAU	There is no substantive evidence that testosterone treatment, when replaced to the normal physiological range, is related to the development of major adverse CV events	Hematocrit >54%	Hematocrit evaluation Electrocardiogram
SIAMS/SIE	Evidence on the safety of TRT on the CV profile is of moderate quality	Recent CV event	Hematocrit evaluation Evaluate global CV risk and associated morbidities, including hematocrit levels Collect a detailed family, personal and clinical history of VTE, thrombophilia-hypofibrinolysis
ICSM	The weight of evidence indicates that TRT is not associated with increased CV risk Preliminary evidence suggests the possibility of beneficial effects of TRT on the CV function	Hematocrit >50%	Hematocrit evaluation
ISAAM	NR	Hematocrit >52% Untreated severe congestive heart failure	Hematocrit evaluation

AUA: American Urological Association; CV: cardiovascular; TRT: testosterone replacement therapy; AACE: American Association of Clinical Endocrinology; BSSM: British Society for Sexual Medicine; EAA: European Academy of Andrology; ES: Endocrine Society; EAU: European Association of Urology; SIAMS: Società Italiana di Andrologia e Medicina della Sessualità; SIE: Società Italiana di Endocrinologia; ICSM: International Consultation on Sexual Medicine; NR: not reported; VTE: venous thromboembolism; ISAAM: International Society for the Study of the Aging Male